Account
Inquiry
Retatrutide (LY3437943) represents a breakthrough in peptide therapeutics as a novel triple agonist targeting glucagon, GIP and GLP-1 receptors. This superior peptides formulation demonstrates significant potential for metabolic disorder research.
Clinical studies indicate retatrutide may effectively address multiple conditions including:
1. Type 2 diabetes management
2. Obesity treatment
3. Non-alcoholic fatty liver disease (NAFLD)
The mechanism of action involves simultaneous activation of three key metabolic receptors, resulting in improved glycemic control and significant weight reduction. Research subjects have shown positive changes in hemoglobin A1c levels, blood pressure, and LDL cholesterol profiles.
As a superior peptides product, our retatrutide is manufactured under strict quality controls to ensure research-grade purity and consistency. The white lyophilized powder maintains excellent water solubility (5mg/ml) for experimental applications.
This pharmaceutical intermediate is provided for research use only, not for human consumption. Proper storage at -20°C preserves stability throughout the 2-year shelf life.
